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Adrenocortical tumors in children 18 years old and 
younger
Min Jeng Cho, Dae Yeon Kim, Seong Chul Kim, Tae Hoon Kim, In Koo Kim
Division of Pediatric Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Purpose: Pediatric adrenocortical tumors (ACTs) are rare. We reviewed findings in 8 children, 18 years of age or younger, di-
agnosed with ACT in our institution over the past 15 years. Methods: We retrospectively reviewed 8 children with ACTs 
treated between 1996 and 2010. Results: Three girls and 5 boys were treated for ACTs; their median age at presentation was 
144 months (range, 28 months to 18 years). Seven patients showed signs of endocrine dysfunction, 4 with Cushing syndrome, 
2 with virilization, and 1 with hyperaldosteronism. One patient, with symptoms of hematuria, underwent a computed to-
mography scan, which showed an adrenal mass. The median duration of symptoms prior to resection was 6 months (range, 
1 to 24 months). Five patients had adenomas and 3 had carcinomas. All underwent complete resection of the tumor, with lap-
aroscopic adrenalectomy performed on 3 patients with adenoma and 1 with carcinoma. The median tumor weight was 12.5 g 
(range, 1 to 130 g) and the median tumor volume was 18.3 cm
3 (range, 2.2 to 299.2 cm
3). At a median follow-up of 5.1 years 
(range, 4 months to 15 years), all 8 patients remain alive with no recurrence of disease. Conclusion: The characteristics of pe-
diatric ACTs vary considerably. Laboratory findings, clinical hormonal features, and tumor size could not distinguish ad-
enomas from carcinomas before surgery. Complete tumor resection was successful, with no tumor recurrence. However, the 
small number of patients and short follow-up period limit assessments of prognosis. 
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INTRODUCTION
Adrenocortical tumors (ACTs) are rare in children, 
comprising less than 0.2% of all pediatric neoplasms and 
6% of all pediatric adrenal tumors [1]. ACTs usually pres-
ent with symptoms and signs of androgen excess and hy-
percortisolism, and rarely, hyperaldosteronism. To date, 
the rarity of these tumors has not allowed a clear definition 
of clinical presentation and prognostic factors. We re-
viewed findings in 8 children, 18 years of age or younger, 
diagnosed with ACTs in our institution over the past 15 
years.
METHODS
The records of all children with ACTs treated between 
1996 and 2010 were reviewed retrospectively. Information Adrenocortical tumors in children 18 years old and younger
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No. Sex/age Sx  (duration)
a) Lab finding Tumor
Tx Follow-up (mo)
Cortisol DHEA 17-KS 17-OHCS Site Size (cm)
1 M/14 yr Cu (24) ND 238.3 3.9 12.6 Lt 2.7 A 180, NED
2 F/18 yr HTN (24) 9 ND ND ND Lt 2.1 Lap-A 156, NED
3 M/12 yr Cu (6) 22.6 104 12.4 16.8 Lt 2.5 A 51, NED
4 F/2 yr 4 mo V (16) 9.5 87.2 1.2 3 Rt 1.9 Lap-A 8, NED
5 M/7 yr Cu (1) 22.6 1,280 50.8 ND Lt 4.8 Lap-A 4, NED
Sx, symptom; Cortisol, plasma (normal, 5 to 25 ug/dL); DHEA, dehydroepiandrosterone-sulfate (normal, 35 to 430 ug/dL); 17-KS, urine 
17-ketosteroid (normal, 3 to 12 mg/day); 17-OHCS, urine 17-hydroxycorticosteroid (normal, 5 to 23 mL/day); Tx, treatment; Cu, Cushing; 
ND, not done; NED, no evidence of disease; HTN, hypertension; Lt, left; A, adrenalectomy; V, virilization; Rt, right; Lap-A, laparoscopic 
adrenalectomy. 
a)Symptom duration before diagnosis (mo).
Table 1. Clinical presentation and treatment outcomes in patients with adrenocortical adenoma
No. Sex/age
Sx
(duration)
a)
Lab finding Tumor
Tx
Follow-up 
(mo) Cortisol DHEA 17-KS 17-OHCS Site Stage Size (cm)
1 M/7 yr Cu (6 mo) ND 1,080 34.7 ND Rt M 9.5/6
b) A + RL + CTx 116, NED
2 F/2 yr 7 mo V (1 mo) 5.1 213 8.7 ND Lt Lo 5 Lap-A 72, NED
3M / 1 5  y r
c) Hu (1 mo) 5.2 31.2 ND ND Lt Lo 6.5 A 18, NED
Sx, symptom; Cortisol, plasma (normal, 5 to 25 ug/dL); DHEA, dehydroepiandrosterone-sulfate (normal, 35 to 430 ug/dL); 17-KS, urine 
17-ketosteroid (normal, 3 to 12 mg/day); 17-OHCS, urine 17-hydroxycorticosteroid (normal, 5 to 23 mL/day); Tx, treatment; Cu, Cushing; 
ND, not done; Rt, right; M, metastasis; A, adrenalectomy; RL, right lobectomy; CTx, chemotherapy; NED, no evidence of disease; V, 
virilization; Lt, left; Lo, local; Lap-A, laparoscopic adrenalectomy; Hu, hematuria.
a)Symptom duration before diagnosis (mo). 
b)Liver metastasis size. 
c)This patient and his sister were both diagnosed with congenital adrenal 
hyperplasia.
Table 2. Clinical presentation and treatment outcomes of patients with adrenocortical carcinoma
recorded for each patient included age, sex, presenting 
symptoms, diagnostic features, hormonal status, patho-
logical findings, stage of disease, treatment, and outcome.
Tumor stage was determined by the modified Mac-
Farlane staging system [2]. Localized disease was defined 
as tumor confined to one of the adrenal glands; regional 
disease as tumor extending beyond the limits of the adre-
nal gland to the surrounding organs and tissues, including 
the regional lymph nodes; and metastatic disease as dis-
ease accompanied by distant metastases, in the presence 
or absence of regional disease. Patients with neuro-
blastoma, pheochromocytoma, and other tumors meta-
static to the adrenal gland were excluded.
RESULTS 
Three girls and 5 boys were treated for ACTs during the 
15-year study period. Their median age at presentation 
was 144 months (range, 28 months to 18 years). All neo-
plasms were unilateral, with 6 presenting on the left side 
and 2 on the right side. Clinical characteristics of these pa-
tients are shown in Tables 1, 2. 
Seven patients showed signs of endocrine dysfunction, 
the most frequent being Cushing syndrome, consisting of 
hypertension, central obesity, buffalo hump, and moon 
face, observed in 4 patients. Two patients showed viriliza-
tion, including growth of pubic hair and clitoromegaly, 
and one presented with symptoms of hyperaldosteronism 
including hypertension and hypokalemia. The remaining 
patient, who was diagnosed with congenital adrenal hy-
perplasia at age 2 months, has been continuously moni-
tored as an outpatient and has shown symptoms of hema-
turia for 1 month. To assess this patient, we performed a 
computed tomography (CT) scan, which revealed an adre-
nal mass. The hematuria in this patient was a temporary, Min Jeng Cho, et al.
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non-specific symptom and later improved without 
treatment. The median duration of symptoms was 6 
months (range, 1 to 24 months). ACTs were diagnosed us-
ing ultrasound imaging and CT scan. 
Elevated concentrations of plasma cortisol and several 
plasma and urinary steroids were found in some patients. 
However, no positive correlation was observed between 
clinical stage and urinary concentrations of steroid meta-
bolites. All patients received preoperative steroid replace-
ment. 
All patients underwent complete tumor resection via a 
transabdominal approach. The median tumor weight was 
12.5 g (range, 1 to 130 g), and the median tumor volume 
was 18.3 cm
3 (range, 2.2 to 299.2 cm
3). Five patients had an 
adrenocortical adenoma and three had an adrenocortical 
carcinoma. One of the patients with carcinoma who had 
liver metastasis on presentation underwent an adrenalec-
tomy and a right lobectomy simultaneously. Laparoscopic 
adrenalectomy was performed on four patients, 3 with ad-
enoma and 1 with carcinoma. All patients showed macro-
scopically negative margins. There was no perioperative 
mortality. 
Of the 3 carcinoma patients, only patients who showed 
liver metastasis received chemotherapy with cisplatin, 
5-fluorouracil and doxorubicin for a total of 6 cycles. At a 
median follow-up of 5.1 years (range, 4 months to 15 
years), all eight patients remain alive with no evidence of 
disease recurrence. 
DISCUSSION
Epidemiologic data has suggested that ACTs are more 
common in girls than in boys, with a 2.5:1 ratio [3-5], and 
that tumors occur more frequently in the left than in the 
right adrenal gland. We found, however, that, although tu-
mors showed left side predominance, five of our eight pa-
tients were boys. Li Fraumeni and Beckwith-Wiedemann 
syndromes are common anomalies associated with ACTs. 
Congenital anomalies of the kidney and congenital adre-
nal hyperplasia also increase the risk of ACTs [6,7]. The 
steadily increasing incidence of precancerous genetic syn-
dromes of the adrenal glands and the poor prognosis of 
patients with adrenocortical carcinomas force children 
with endocrine disorders to go through a detailed diag-
nostic evaluation and appropriate treatment, as given to 
adults.
ACTs have shown a bimodal age distribution, with 
peaks occurring in the first and fourth to fifth decades of 
life, although these tumors have also been reported to 
peak at age ＜5 years [3,8]. Although younger age at diag-
nosis has been associated with improved survival rate [9], 
other studies have found that age was not prognostic 
[10,11]. We did not observe a correlation between age and 
prognosis, due to the small numbers of patients and their 
ages, with only 2 patients ＜5 years old. Functional tumors 
produce symptoms due to the overproduction of cortical 
hormones, and most children with ACTs show endocrine 
symptoms, in contrast to adults who usually present with 
nonfunctional tumors [12,13]. Of our 8 patients, 7 pre-
sented with evidence of a hormonally active tumor. In gen-
eral, virilization is the most frequent symptom of ACTs, 
followed by Cushing syndrome, with hyperaldostero-
nism being extremely rare. Of our 8 patients, four dis-
played the characteristics of Cushing syndrome and only 
the 2 youngest patients developed virilization. The patient 
with hypertension showed a decrease in renin concen-
tration and an increase in aldosterone concentration. 
Although functional tumors are diagnosed earlier than 
nonfunctional tumors, the latter are frequently associated 
with distant metastases, inoperable abdominal masses, 
and pain [14,15]. Another study, however, reported no cor-
relation between tumor type, functional vs. nonfunc-
tional, or the time of symptom appearance and tumor 
stage [5]. Rather, the rapid growth rate of cancer cells in 
carcinomas results in nonspecific symptoms before the 
symptoms caused by hormones [16]. Of our 3 carcinoma 
patients, one exhibited no symptoms and the other two 
showed rapid development of symptoms, over 1 and 6 
months, respectively. The patient with the largest ad-
enoma also showed rapid development of hormonal 
symptoms. Thus, despite the small number of our pa-
tients, our findings suggest that tumor type, functional or 
nonfunctional, cannot aid in distinguishing adenomas 
from carcinomas. 
Increased concentrations of cortisol, dehydroepian-Adrenocortical tumors in children 18 years old and younger
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drosterone-sulfate, urine 17-ketosteroid, and urine 17- hy-
droxycorticosteroid before surgery may indicate carcino-
ma rather than adenoma [17], with a positive correlation 
between tumor stage and hormone concentration level [5]. 
We found, however, that many of our patients with func-
tional tumors showed normal hormone levels, and that 
only one patient with adenoma and one with carcinoma 
had increased hormone concentrations. Since only 3 of our 
patients had carcinomas, larger studies are needed to de-
termine correlations between laboratory data and clinical 
stage. 
Surgical treatment has long been the cornerstone of 
therapy for ACTs, being the only form of treatment that 
unquestionably cures the tumors or prolongs survival sig-
nificantly [3]. For small tumors, complete resection with-
out radical lymph node dissection (RLND) may be suffi-
cient [18], although the effect of RLND on recurrence rate 
or long-term prognosis in patients with advanced cancer 
has not been determined. At our institution, surgical re-
section of an ACTs includes macroscopically negative 
margins and no tumor spillage, with node dissection only 
if lymph nodes are grossly enlarged. 
Laparoscopic adrenalectomy has recently been per-
formed in pediatric patients as well as in adults [19-22]. 
Although most of these patients have benign diseases, lap-
aroscopic adrenalectomy has shown the same oncologic 
results as open surgery in children with neuroblastoma 
and other adrenal cancers. Using this technique, we ob-
served macroscopically negative margins, without tumor 
spillage, after complete resection of 3 adenomas and 1 
carcinoma. Although the first operation took a long time, 
later operations were finished within 2 hours, with no sig-
nificant differences from open surgery. Spillage should be 
avoided during complete resection since adenomas and 
carcinomas cannot be completely distinguished before 
surgery.
 Due to the relatively small number of patients with 
ACTs, the role of chemotherapy is still unclear. Mitotane, 
an insecticide derivative that causes adrenocortical ne-
crosis, has been used in adults, but its efficacy in children 
has not been well studied [23,24]. Chemotherapy gen-
erally is reserved for patients with recurrent or metastatic 
disease or those at high risk of relapse [25]. Therefore, also 
in our study, chemotherapy was conducted only for pa-
tients with liver metastasis after surgery and not carried 
out on the other two carcinoma patients. Radiotherapy al-
so has not been found to improve survival rate, although 
patients have shown complete remission [26,27].
Statistically significantly prolonged survival rates has 
been reported in girls, localized tumors, patients who un-
derwent extirpative procedure, and patients with a dis-
ease-free interval of ＞12 months [28]. Michalkiewicz et al. 
[29] found that patients with tumors ＜200 cm
3 in volume 
and ＜100 g in weight that were completely resected had 
an excellent prognosis, and the long-term survival rate of 
children with adrenocortical carcinoma has been reported 
to be between 10% and 46% [30]. All of our 8 patients 
showed positive results from complete resection, with no 
evidence of recurrence. However, the small number of pa-
tients and the short follow-up period limit assessments of 
prognosis. 
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article 
was reported.
REFERENCES
1. Chudler RM, Kay R. Adrenocortical carcinoma in children. 
Urol Clin North Am 1989;16:469-79.
2. Sullivan M, Boileau M, Hodges CV. Adrenal cortical 
carcinoma. J Urol 1978;120:660-5.
3. Liou LS, Kay R. Adrenocortical carcinoma in children. 
Review and recent innovations. Urol Clin North Am 
2000;27:403-21.
4. Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, 
Sambaio GA, Cat I. Adrenocortical carcinoma in children: 
a study of 40 cases. J Clin Oncol 1990;8:67-74.
5. Ciftci AO, Senocak ME, Tanyel FC, Buyukpamukcu N. 
Adrenocortical tumors in children. J Pediatr Surg 2001;36: 
549-54.
6. Ciftci AO, Salman AB, Tanyel FC, Hicsonmez A. Bilateral 
multiple adrenal pseudocysts associated with incomplete 
Beckwith-Wiedemann Syndrome. J Pediatr Surg 1997;32: 
1388-90.
7. Latronico AC, Chrousos GP. Extensive personal experi-
ence: adrenocortical tumors. J Clin Endocrinol Metab 
1997;82:1317-24.Min Jeng Cho, et al.
250 thesurgery.or.kr
8. Rescorla FJ. Malignant adrenal tumors. Semin Pediatr Surg 
2006;15:48-56.
9. Sabbaga CC, Avilla SG, Schulz C, Garbers JC, Blucher D. 
Adrenocortical carcinoma in children: clinical aspects and 
prognosis. J Pediatr Surg 1993;28:841-3.
10. Sbragia L, Oliveira-Filho AG, Vassallo J, Pinto GA, Guerra- 
Junior G, Bustorff-Silva J. Adrenocortical tumors in Brazi-
lian children: immunohistochemical markers and prog-
nostic factors. Arch Pathol Lab Med 2005;129:1127-31.
11. Hanna AM, Pham TH, Askegard-Giesmann JR, Grams JM, 
Iqbal CW, Stavlo P, et al. Outcome of adrenocortical tumors 
in children. J Pediatr Surg 2008;43:843-9.
12. Cagle PT, Hough AJ, Pysher TJ, Page DL, Johnson EH, 
Kirkland RT, et al. Comparison of adrenal cortical tumors 
in children and adults. Cancer 1986;57:2235-7.
13. Hur JI, Hong CG, Song KY, Choi SH, Yoon SS, Lee S, et al. 
Adrenocortical carcinoma: report of two cases. J Korean 
Surg Soc 1999;57:285-94. 
14. Nader S, Hickey RC, Sellin RV, Samaan NA. Adrenal cort-
ical carcinoma. A study of 77 cases. Cancer 1983;52:707-11.
15. Lipsett MB, Hertz R, Ross GT. Clinical and pathophysio-
logic aspects of adrenocortical carcinoma. Am J Med 
1963;35:374-83.
16. Chai YJ, Moon SB, Jung SE, Lee SC, Park KW. Clinical re-
view of the pediatric primary adrenocortical tumors. J 
Korean Assoc Pediatr Surg 2007;13:162-8.
17. Neblett WW, Frexes-Steed M, Scott HW Jr. Experience with 
adrenocortical neoplasms in childhood. Am Surg 1987;53: 
117-25.
18. Stewart JN, Flageole H, Kavan P. A surgical approach to 
adrenocortical tumors in children: the mainstay of 
treatment. J Pediatr Surg 2004;39:759-63.
19. Nerli RB, Reddy MN, Guntaka A, Patil S, Hiremath M. 
Laparoscopic adrenalectomy for adrenal masses in 
children. J Pediatr Urol 2011;7:182-6.
2 0 . K a d a m b a  P ,  H a b i b  Z ,  R o s s i  L .  E x p e r i e n c e  w i t h  l a p a r o -
scopic adrenalectomy in children. J Pediatr Surg 2004;39: 
764-7.
21. Laje P, Mattei PA. Laparoscopic adrenalectomy for adrenal 
tumors in children: a case series. J Laparoendosc Adv Surg 
Tech A 2009;19 Suppl 1:S27-9.
22. Romano P, Avolio L, Martucciello G, Steyaert H, Valla JS. 
Adrenal masses in children: the role of minimally invasive 
surgery. Surg Laparosc Endosc Percutan Tech 2007;17: 
504-7.
23. Teinturier C, Pauchard MS, Brugieres L, Landais P, 
Chaussain JL, Bougneres PF. Clinical and prognostic as-
pects of adrenocortical neoplasms in childhood. Med 
Pediatr Oncol 1999;32:106-11.
24. Mayer SK, Oligny LL, Deal C, Yazbeck S, Gagne N, 
Blanchard H. Childhood adrenocortical tumors: case series 
and reevaluation of prognosis: a 24-year experience. J 
Pediatr Surg 1997;32:911-5.
25. Lack EE, Mulvihill JJ, Travis WD, Kozakewich HP. Adrenal 
cortical neoplasms in the pediatric and adolescent age 
group. Clinicopathologic study of 30 cases with emphasis 
on epidemiological and prognostic factors. Pathol Annu 
1992;27 Pt 1:1-53.
26. Johnson DH, Greco FA. Treatment of metastatic adrenal 
cortical carcinoma with cisplatin and etoposide (VP-16). 
Cancer 1986;58:2198-202.
27. Percarpio B, Knowlton AH. Radiation therapy of adrenal 
cortical carcinoma. Acta Radiol Ther Phys Biol 1976;15: 
288-92.
28. Didolkar MS, Bescher RA, Elias EG, Moore RH. Natural 
history of adrenal cortical carcinoma: a clinicopathologic 
study of 42 patients. Cancer 1981;47:2153-61.
29. Michalkiewicz EL, Sandrini R, Bugg MF, Cristofani L, 
Caran E, Cardoso AM, et al. Clinical characteristics of 
small functioning adrenocortical tumors in children. Med 
Pediatr Oncol 1997;28:175-8.
30. Sawin RS. Functioning adrenal neoplasms. Semin Pediatr 
Surg 1997;6:156-63.